Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma

Lenvatinib is an approved first-line therapy for unresectable hepatocellular carcinoma (HCC), but the effect of dose modification on its efficacy is unclear. We analyzed the relationship between the relative dose intensity during the initial 4 weeks of therapy [4W-relative dose intensity (RDI)] and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Kirino, Sakura, Tsuchiya, Kaoru, Kurosaki, Masayuki, Kaneko, Shun, Inada, Kento, Yamashita, Koji, Osawa, Leona, Hayakawa, Yuka, Sekiguchi, Shuhei, Okada, Mao, Wang, Wan, Higuchi, Mayu, Takaura, Kenta, Maeyashiki, Chiaki, Tamaki, Nobuharu, Yasui, Yutaka, Nakanishi, Hiroyuki, Itakura, Jun, Takahashi, Yuka, Asahina, Yasuhiro, Izumi, Namiki
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2020
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7170221/
https://ncbi.nlm.nih.gov/pubmed/32310967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0231828
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky